Notably, the resistance of prostate cancer cells to androgen-deprivation can be attenuated either by RNAi-mediated knockdown of LRH-1 expression, or by pharmacological suppression of LRH-1 activity with a LRH-1-specific inverse agonist ML-180 [23], suggesting that targeting LRH-1 could be a valuable therapeutic strategy approach for CRPC management. The gene discussed is NR5A2; the disease is prostate cancer.